GH1 and acromegaly: The follow‐up phase III study of the long‐acting formulation, pasireotide LAR, showed greater efficacy than octreotide LAR in achieving target GH levels of <2.5 μg/L and normal IGF‐I levels (31.3% vs 19.2%, respectively) in patients with uncontrolled acromegaly who had not previously received medical therapy.23